WO2019194772A2 - Modified release formulations of fesoterodine - Google Patents
Modified release formulations of fesoterodine Download PDFInfo
- Publication number
- WO2019194772A2 WO2019194772A2 PCT/TR2018/050855 TR2018050855W WO2019194772A2 WO 2019194772 A2 WO2019194772 A2 WO 2019194772A2 TR 2018050855 W TR2018050855 W TR 2018050855W WO 2019194772 A2 WO2019194772 A2 WO 2019194772A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modified release
- weight
- release formulation
- formulation according
- fesoterodine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Abstract
The present invention relates to modified release formulations comprising fesoterodine or a pharmaceutically acceptable salt thereof with at least two sugars or its derivatives as stabilizers.
Description
MODIFIED RELEASE FORMULATIONS OF FESOTERODINE
Field of the Invention
The present invention relates to modified release formulations comprising fesoterodine or a pharmaceutically acceptable salt thereof with at least two sugars or its derivatives as stabilizers.
Background of the Invention
The chemical name of fesoterodine is (2-[(1 R)-3-[bis(1 -methylethyl) amino]-1 - phenylpropyl]-4-hydroxymethylphenyl isobutyrate or alternatively R-(+)-isobutyric acid 2- (3-diisopropylamino-1 -phenylpropyl)-4-hydroxymethylphenyl ester). Its empirical formula is C3OH41N07, corresponding to a molecular weight of 527.66 having the following structural formula:
Formula I
The drug fesoterodine fumarate is the active ingredient in a product being sold as TOVIAZ® tablets to treat urinary incontinence and frequency problems. Inactive ingredients are glyceryl behenate, hypromellose, lactose monohydrate, soya lecithin, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and xylitol.
Fesoterodine is known in the art for its potency in treating urinary incontinence. However, fesoterodine may exhibit substantial degradation under stress conditions. It is believed that hydrolyzation and oxidation are among the major mechanisms resulting in degradation.
Synthesis pathways for fesoterodine are described EP 1 077 912 B1 . Salts of fesoterodine is described in EP 1 230 209 B1.
WO 2010/043408 discloses a microencapsuled fesoterodine composition which distinct from a homogenous mixture of fesoterodine particle with a matrix, is composed of a particle containing fesoterodine and a shell surrounding fesoterodine containing particle. However, in the case, the stability of compositions is provided a complex-structured pharmaceutical composition.
There is thus still a need for a physically and chemically stable composition fesoterodine that are stable against fesoterodine degradation over an extended period of time. In the present invention, stabilizers with binding properties was used, so while the stable formulation is provided without using extra load of excipients, also the formulation provide desired dissolution profile and excellent pharmacotechnical properties such as flowability, compressibility and homogeneity. Also, the formulation has been developed by using standard techniques which is simple and cost-effective method.
Detailed Description of the Invention
The main object of the present invention is to provide pharmaceutical formulations of fesoterodine which are more stable against degradation over storage period and also provide desired modified release of the drug.
Another object of the present invention is to provide a formulation which is characterized by the desired dissolution profile and excellent pharmacotechnical properties, such as flowability, compressibility and homogeneity.
The term "fesoterodine" as used throughout the specification refers to not only fesoterodine, but also its other pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pharmaceutically acceptable prodrugs thereof.
The term “stability” as used herein includes both chemical stability, physical and polymorphic stability.
The term“modified release phase” refers to any pharmaceutical formulation that maintain constant levels of a drug in the patient's bloodstream by releasing the drug over an extended period of time. Modified release is formulated to release the active ingredient gradually and predictably over a 12-hour to 24-hour period. Modified release formulations are also referred to controlled release, sustained release, delayed release, extended release or repeat action systems or mixtures thereof.
In this invention, the modified release formulation comprises fesoterodine and at least two sugars or its derivatives as stabilizers wherein the sugars or its derivatives are selected from sucrose, fructose, maltitol, mannitol, lactitol or mixtures thereof, optionally granulated and optionally compressed.
In one embodiment of this present invention, the amount of fesoterodine is between 0.5% and 25.0% w/w of the composition, preferably it is between 0.5% and 15.0% w/w of the composition.
In one embodiment of this present invention, the ratio of fesoterodine to stabilizers is in the range of between 1 :20 and 20:1 by weight, preferably between 1 :15 and 15:1 by weight.
Fructose is more soluble than other sugars and hard to crystallize because it is more hygroscopic and holds onto water stronger than the others. This means that fructose can be used to extend the shelf life of composition more than other sugars. But, fructose has some side-effects when is not used in reasonable amounts. Thereof, fructose-sucrose mixture is used. Surprisingly, it has been found that using both fructose and sucrose as the stabilizer provides improved stability and better dissolution rate to the formulation and prevented degradation of fesoterodine.
In one embodiment of this present invention, the modified release formulation comprises the fructose-sucrose mixture as a stabilizer.
According to one embodiment in the present invention, the fructose-sucrose mixture is a stabilizer which have binder properties. In addition, it further enhances excellent pharmacotechnical properties (flowability, compressibility and homogeneity).
In one embodiment of this present invention, the amount of the fructose-sucrose mixture is between 3.0% and 35.0% by weight of the composition, preferably it is between 10.0% and 31.0% by weight., more preferably it is between 14.0% and 29.0% by weight.
In one embodiment of this present invention, the ratio of fructose to sucrose is in the range of between 1 :50 and 50:1 by weight, preferably between 40:1 and 1 :40 by weight, more preferably between 35:1 and 1 :35 by weight. These ratios are important in order to provide stability in the present formulation.
The pharmaceutically acceptable excipient which is used in the formulation and process for preparation of the formulation of the present invention must be compatible with fesoterodine.
According to another embodiment of this invention, modified release formulation further comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising diluents, rate controlling polymers, lubricants, coating agents or the mixtures thereof.
Suitable diluents are selected from the group lactose monohydrate, microcrystalline cellulose, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulfate, microcrystalline silicified cellulose, powdered cellulose, dextrates, dextrose, fructose, lactitol. lactose anhydrous, lactose dihydrate or mixtures thereof. The amounts of diluents are between 10.0% and 28.0% w/w of the composition, preferably the amounts of diluents are between 13.0% and 25.0% w/w of the composition.
Modified release formulations are preferred. At this invention, formulation is prepared using rate controlling polymers.
Suitable rate controlling polymers are selected from the group comprising hydroxypropylmethyl cellulose, carbomer, xanthan gum, polyethylene oxides, glyceryl dibehenate, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, methylcellulose, carboxymethylcellulose and its salts, polyacrylates, , methylacrylates, polyethylene glycols, starch derivatives, galactomannans, polysaccharides, polyalcohols, acrylic acid or its derivatives, glycerol monostearate, polyanhydrides, methylacrylates, polyamides, polycarbonates, polyalkylene, polyalkylene glycols, polyalkylene oxides, polyvinyl alcohols, polyvinyl ethers, polyvinylpyrrolidone,
polymers of acrylic and methacrylic esters, polylactides, polyorthoesters, poly(fumaric acid) or mixtures thereof.
Particularly, preferred rate controlling polymers are selected from a group comprising of hydroxypropylmethyl cellulose, carbomer, xanthan gum, polyethylene oxides, glyceryl dibehenate or mixture thereof. The selected controlled release polymers are preferably present in an amount that allows for the formation of a gel matrix from which the active ingredient is gradually released.
The amount of the rate controlling polymers are in the modified release formulation between 10.0% and 60.0% w/w of the formulation, preferably between 20.0% and 55.0% w/w of the formulation
In one embodiment of this present invention, rate controlling polymers are hydroxypropylmethyl cellulose, polyethylene oxides and glyceryl dibehenate.
In one embodiment of this present invention, the ratio of fesoterodine to hydroxypropylmethyl cellulose is in the range of between 10:1 and 1 :10 by weight, preferably this ratio is in the range of between 8:1 and 1 :8 by weight. While this ratio helps to protect improved stability in the present formulation, at the same time provide desired modified release of the drug.
The amount of the hydroxypropylmethyl cellulose is in the pharmaceutical composition between 10.0% and 40.0% w/w of the formulation.
Suitable lubricants are selected from the group from talc, calcium silicate, powdered cellulose, starch, colloidal silicon dioxide or mixtures thereof. Lubricants are between 0.01% and 4.0% w/w of the formulation.
In another embodiment of this present invention, the compositions comprise a film coating. A film coat on the tablet protects from moisture and further contributes to the ease with which it can be swallowed. Preferably, a moisture barrier film coating is used in order to minimize the degradation of fesoterodine due to moisture.
Suitable coating agents are selected from the group comprising polyvinyl alcohol (PVA), talc, polymethacrylates, hydroxypropyl methylcellulose, sodium lauryl sulfate, glyceryl
monocaprylocaprate, lactose monohydrate, hydroxypropyl cellulose, polyethylene glycol (PEG), polyvinyl alcohol-polyethylene glycol copolymers, ethylcellulose dispersions, polyvinylpyrrolidone, polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, macrogol, coloring agent or mixtures thereof.
Suitable coloring agents are selected from the group comprising ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
Solid oral dosage is used for having effective stability and bioavailability. In another embodiment of the present invention, the modified release formulation is in a solid oral dosage form.
The modified release formulation according to the present invention is in the form of tablet, capsule, pastilles, strip.
The modified release formulation according to the present invention is in the form of tablet. Tablet is film-coated tablets, bilayer tablets, inlay tablets, orally disintegrating tablets, compressed tablets, coated or uncoated tablets, multilayer tablets, mini tablets, buccal tablets, sublingual tablets, effervescent tablets, immediate release tablets, modified release tablets, gastric disintegrating tablets, chewable tablets, dispersing tablets or lozenges.
Preferably, the modified release formulation is in the form of film-coated tablet.
In this present invention, the tablet comprises at least one type of particle, for example; mini-tablet, pellets, agglomerates, granules, powder, liposomes, sphericles or mixtures thereof.
An embodiment of this present invention, each type of particle comprises at least one active agent.
In one embodiment of the invention, the modified release formulation comprises;
0.5% - 25.0% by weight of fesoterodine
3.0% - 35.0% by weight of fructose
0.05% - 20.0% by weight of sucrose
5.0% - 32.0% by weight of lactose monohydrate
1.0% - 25.0% by weight of glyceryl dibehenate
5.0% - 35.0% by weight of microcrystalline cellulose
0.05% - 10.0% by weight of talc
10.0% - 40.0% by weight of hydroxypropyl methylcellulose
1.0% - 25.0% by weight of polyethylene oxides
2.0% - 10.0% by weight of coating
In one embodiment of the invention, the modified release formulation comprises;
0.5% - 5.0% by weight of fesoterodine
19.0% - 25.0% by weight of fructose
0.1 % - 3.0% by weight of sucrose
15.0% - 21 .0% by weight of lactose monohydrate
3.0% - 10.0% by weight of glyceryl dibehenate
12.0% - 20.0% by weight of microcrystalline cellulose
0.1 % - 3.0% by weight of talc
10.0% - 40.0% by weight of hydroxypropyl methylcellulose
4.0% - 12.0% by weight of polyethylene oxides
3.0% - 8.0% by weight of coating
The modified release formulation of the present invention may prepared by direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying or solvent evaporation.
Preferably, the modified release formulation is prepared wet granulation which is simple and cost-effective method. Also, this process helps to provide stability and dissolution profile of the tablet.
Process for preparing the modified release formulation comprises the following steps; a) Mixing fesoterodine, fructose and sucrose
b) Granulating the mixture with water then, sieving
c) Drying the mixture at 40°C until the humidity is less than 0.5%, then sieving the mixture
d) Adding lactose monohydrate, glyceryl dibehenate, microcrystalline cellulose, hydroxypropyl methylcellulose, polyethylene oxides and then mixing e) Then, adding talc and mixing
f) Then, pressing to form tablet
g) Coating tablets with coating agent
It has been found that using wet granulation process, wherein granulating fesoterodine and the fructose-sucrose mixture as a stabilizer with the addition of excipients for wet granulation showed an improved stability of fesoterodine in the granulate and in the pharmaceutical formulation.
Also, it has been found that when the formulation is prepared with using water based granulation, resulting formulations possess improved stability.
The given below examples describes the modified release formulation comprising fesoterodine.
Example 1 : Modified release formulation comprising fesoterodine
The process for preparation of the modified release formulation comprises the following steps:
a) Mixing fesoterodine and at least two stabilizers
b) Granulating the mixture with water then, sieving
c) drying the mixture at 40°C until the humidity is less than 0.5%, then sieving the mixture
d) Adding diluents, rate controlling polymers and then mixing
e) Then, adding lubricants and mixing
f) Then, pressing to form tablet
g) Optionally, coating tablets with coating agent
Example 2: Modified release formulation comprising fesoterodine
Process for example 2:
The process for preparation of the modified release formulation comprises the following steps:
a) Mixing fesoterodine, fructose and sucrose
b) Granulating the mixture with water then, sieving
c) Drying the mixture at 40°C until the humidity is less than 0.5%, then sieving the mixture
d) Adding lactose monohydrate, glyceryl dibehenate, microcrystalline cellulose, hydroxypropyl methylcellulose, polyethylene oxides and then mixing
e) Then, adding talc and mixing
f) Then, pressing to form tablet
g) Optionally, coating tablets with coating agent Example 3: Modified release formulation comprising fesoterodine
Process for example 3:
The process for preparation of the modified release formulation comprises the following steps:
h) Mixing fesoterodine, fructose and sucrose
i) Granulating the mixture with water then, sieving
j) drying the mixture at 40°C until the humidity is less than 0.5%, then sieving the mixture
k) Adding lactose monohydrate, glyceryl dibehenate, microcrystalline cellulose, hydroxypropyl methylcellulose, polyethylene oxides and then mixing
L) Then, adding talc and mixing
m) Then, pressing to form tablet
n) Optionally, coating tablets with coating agent
Claims
1. A modified release formulation comprising fesoterodine and at least two sugars or its derivatives as stabilizers wherein the sugars or its derivatives are selected from sucrose, fructose, maltitol, mannitol, lactitol or mixtures thereof.
2. The modified release formulation according to claim 1 , wherein the amount of fesoterodine is between 0.5% and 25.0% w/w of the composition.
3. The modified release formulation according to claim 1 , wherein the ratio of fesoterodine to stabilizers is in the range of between 1 :20 and 20:1 by weight, preferably between 1 :15 and 15:1 by weight.
4. The modified release formulation according to claim 1 , wherein stabilizers are the sucrose-fructose mixture.
5. The modified release formulation according to claim 4, wherein the amount of the fructose-sucrose mixture is between 3.0% and 35.0% w/w of the total composition.
6. The modified release formulation according to claim 4, wherein the ratio of fructose to sucrose is in the range of between 1 :50 and 50:1 by weight, preferably between 40:1 and 1 :40 by weight.
7. The modified release formulation according to claim 1 , further comprising at least one pharmaceutically acceptable excipient which is selected from the group comprising diluents, rate controlling polymers, lubricants, coating agents or mixtures thereof.
8. The modified release formulation according to claim 7, wherein rate controlling polymers are selected from the group comprising hydroxypropylmethyl cellulose, carbomer, xanthan gum, polyethylene oxides, glyceryl dibehenate, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, methylcellulose, carboxymethylcellulose and its salts, polyacrylates, , methylacrylates, polyethylene glycols, starch derivatives, galactomannans, polysaccharides, polyalcohols, acrylic acid or its derivatives, glycerol monostearate, polyanhydrides, methylacrylates, polyamides, polycarbonates, polyalkylene, polyalkylene glycols, polyalkylene oxides, polyvinyl alcohols, polyvinyl ethers,
polyvinylpyrrolidone, polymers of acrylic and methacrylic esters, polylactides, polyorthoesters, poly(fumaric acid) or mixtures thereof.
9. The modified release formulation according to claim 8, wherein the rate controlling polymers are selected from a group comprising of hydroxypropylmethyl cellulose, carbomer, xanthan gum, polyethylene oxides, glyceryl dibehenate or mixture thereof.
10. The modified release formulation according to claim 9, wherein the amount of the rate controlling polymers in the pharmaceutical composition is between 10.0% and 60.0% w/w, preferably between 20.0% and 55.0% w/w of the composition.
1 1 . The modified release formulation according to claim 9, wherein rate controlling polymers are hydroxypropylmethyl cellulose, polyethylene oxides or glyceryl dibehenate or their mixtures.
12. The modified release formulation according to claim 1 1 , wherein the ratio of fesoterodine to hydroxypropylmethyl cellulose is in the range of between 10:1 and 1 :10 by weight by weight.
13. The modified release formulation according to claim 1 1 or 12, wherein the amount of the hydroxypropylmethyl cellulose in the pharmaceutical composition is between 10.0% and 40.0% w/w of the composition.
14. The modified release formulation according to any preceding claims, the formulation comprising;
0.5% - 25.0% by weight of fesoterodine
3.0% - 35.0% by weight of fructose
0.05% - 20.0% by weight of sucrose
5.0% - 32.0% by weight of lactose monohydrate
1.0% - 25.0% by weight of glyceryl dibehenate
5.0% - 35.0% by weight of microcrystalline cellulose
0.05% - 10.0% by weight of talc
10.0% - 40.0% by weight of hydroxypropyl methylcellulose
1.0% - 25.0% by weight of polyethylene oxides
2.0% - 10.0% by weight of coating
15. Process for preparing the modified release formulation according to claim 14, the formulation comprising the following steps;
a) Mixing fesoterodine, fructose and sucrose
b) Granulating the mixture with water then, sieving
c) Drying the mixture, then sieving the mixture
d) Adding lactose monohydrate, glyceryl dibehenate, microcrystalline cellulose, hydroxypropyl methylcellulose, polyethylene oxides and then mixing e) Then, adding talc and mixing
f) Then, pressing to form tablet
g) Coating tablets with coating agent
16. The modified release formulation according to any preceding claims, wherein the formulation is in the form of tablet, capsule, pastilles, strip.
17. The modified release formulation according to claim 16, wherein the formulation is in the form of a tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18913635.1A EP3731931A4 (en) | 2017-12-25 | 2018-12-21 | Modified release formulations of fesoterodine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2017/21437A TR201721437A2 (en) | 2017-12-25 | 2017-12-25 | FORMULATIONS OF FESOTHERODY PROVIDING MODIFIED EMISSION |
| TR2017/21437 | 2017-12-25 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2019194772A2 true WO2019194772A2 (en) | 2019-10-10 |
| WO2019194772A3 WO2019194772A3 (en) | 2020-01-02 |
| WO2019194772A9 WO2019194772A9 (en) | 2020-03-19 |
Family
ID=67900979
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2018/050855 WO2019194772A2 (en) | 2017-12-25 | 2018-12-21 | Modified release formulations of fesoterodine |
| PCT/TR2018/050859 WO2019221684A2 (en) | 2017-12-25 | 2018-12-21 | The bilayer tablet formulation of fesoterodine |
| PCT/TR2018/050858 WO2019209220A2 (en) | 2017-12-25 | 2018-12-21 | Extended release compositions of fesoterodine |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2018/050859 WO2019221684A2 (en) | 2017-12-25 | 2018-12-21 | The bilayer tablet formulation of fesoterodine |
| PCT/TR2018/050858 WO2019209220A2 (en) | 2017-12-25 | 2018-12-21 | Extended release compositions of fesoterodine |
Country Status (3)
| Country | Link |
|---|---|
| EP (4) | EP3731826A2 (en) |
| TR (4) | TR201721437A2 (en) |
| WO (3) | WO2019194772A2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130236544A1 (en) | 2012-03-08 | 2013-09-12 | Dr. Reddy's Laboratories Ltd. | Stable pharmaceutical compositions of fesoterodine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0957073A1 (en) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE19955190A1 (en) | 1999-11-16 | 2001-06-21 | Sanol Arznei Schwarz Gmbh | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
| US7807715B2 (en) | 2006-06-09 | 2010-10-05 | Ucb Pharma Gmbh | Pharmaceutical compositions comprising fesoterodine |
| ATE517619T1 (en) * | 2006-06-09 | 2011-08-15 | Ucb Pharma Gmbh | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE |
| WO2010043408A2 (en) | 2008-10-17 | 2010-04-22 | Ratiopharm Gmbh | Microencapsulated fesoterodine |
| EP2508173A1 (en) * | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Stabilized pharmaceutical composition comprising fesoterodine |
| US20150182629A1 (en) * | 2012-07-02 | 2015-07-02 | Hetero Research Foundation | Stable compositions of fesoterodine |
| IN2013MU02631A (en) * | 2013-08-12 | 2015-06-19 | Genepharm India Pvt Ltd |
-
2017
- 2017-12-25 TR TR2017/21437A patent/TR201721437A2/en unknown
-
2018
- 2018-12-13 TR TR2018/19274A patent/TR201819274A2/en unknown
- 2018-12-13 TR TR2018/19312A patent/TR201819312A2/en unknown
- 2018-12-17 TR TR2018/19578A patent/TR201819578A2/en unknown
- 2018-12-21 EP EP18915776.1A patent/EP3731826A2/en active Pending
- 2018-12-21 WO PCT/TR2018/050855 patent/WO2019194772A2/en unknown
- 2018-12-21 EP EP18849451.2A patent/EP3731829A1/en active Pending
- 2018-12-21 EP EP18913635.1A patent/EP3731931A4/en active Pending
- 2018-12-21 EP EP18911327.7A patent/EP3731825A2/en active Pending
- 2018-12-21 WO PCT/TR2018/050859 patent/WO2019221684A2/en unknown
- 2018-12-21 WO PCT/TR2018/050858 patent/WO2019209220A2/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130236544A1 (en) | 2012-03-08 | 2013-09-12 | Dr. Reddy's Laboratories Ltd. | Stable pharmaceutical compositions of fesoterodine |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3731931A2 (en) | 2020-11-04 |
| TR201721437A2 (en) | 2019-07-22 |
| WO2019209220A3 (en) | 2019-12-26 |
| EP3731931A4 (en) | 2021-11-03 |
| EP3731829A1 (en) | 2020-11-04 |
| WO2019221684A2 (en) | 2019-11-21 |
| TR201819312A2 (en) | 2019-07-22 |
| WO2019194772A3 (en) | 2020-01-02 |
| EP3731825A2 (en) | 2020-11-04 |
| WO2019209220A2 (en) | 2019-10-31 |
| WO2019194772A9 (en) | 2020-03-19 |
| TR201819578A2 (en) | 2019-07-22 |
| TR201819274A2 (en) | 2019-07-22 |
| WO2019221684A3 (en) | 2020-01-30 |
| EP3731826A2 (en) | 2020-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220395502A1 (en) | Pharmaceutical compositions comprising azd9291 | |
| NZ555901A (en) | Matrix type sustained-release preparation containing donepezil hydrochloride and / or memantine hydrochloride | |
| NZ555693A (en) | Matrix type sustained-release preparation containing donepezil | |
| US7220762B1 (en) | Methods for stabilizing benzimidazole compounds | |
| US20090324728A1 (en) | Pharmaceutical compositions comprising amorphous benzimidazole compounds | |
| US20200188380A1 (en) | Pharmaceutical composition comprising lenvatinib mesylate | |
| JP7094944B2 (en) | Pharmaceutical composition containing rosuvastatin and ezetimibe and method for preparing the same | |
| WO2017208136A1 (en) | Pharmaceutical composition of dapagliflozin co-crystal | |
| US7959948B2 (en) | Pharmaceutical composition of quetiapine fumarate | |
| EP3236952B1 (en) | Pharmaceutical tablet composition | |
| CA3085455C (en) | A solid oral dosage form comprising linagliptin | |
| WO2019194772A2 (en) | Modified release formulations of fesoterodine | |
| JP7370126B2 (en) | Pharmaceutical tablets containing erlotinib as the active ingredient | |
| US20110223245A1 (en) | Controlled-release formulations of pramipexole | |
| WO2020055359A2 (en) | Oral dosage form of sorafenib tosylate | |
| JP7370124B2 (en) | Pharmaceutical tablets containing erlotinib as the active ingredient | |
| WO2023195954A1 (en) | A film coated tablet comprising a solid dispersion of selexi̇pag | |
| CA3187241A1 (en) | Pharmaceutical compositions comprising ribociclib | |
| WO2023195955A1 (en) | A film coated tablet comprising selexi̇pag and its preparation process | |
| WO2023195957A1 (en) | A film coated tablet comprising selexi̇pag processed with wet granulation | |
| WO2022085015A1 (en) | A solid oral composition of teriflunomide | |
| WO2022162687A1 (en) | Pharmaceutical compositions comprising nilotinib | |
| WO2023195953A1 (en) | A film coated tablet comprising selexi̇pag | |
| WO2023195956A1 (en) | A film coated tablet comprising selexi̇pag and at least one filler | |
| WO2022153330A1 (en) | Pharmaceutical compositions comprising acalabrutinib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18913635 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2018913635 Country of ref document: EP Effective date: 20200727 |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18913635 Country of ref document: EP Kind code of ref document: A2 |